Human LATS2/KPM ORF/cDNA clone-Lentivirus particle (NM_014572)

Cat. No.: vGMLP-SPh-020

Pre-made Human LATS2/KPM Lentiviral expression plasmid for LATS2 lentivirus packaging, LATS2 lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

The GM Vector Core (GMVC) specializes in custom lentivirus development and offers a range of lentivirus manufacturing solutions, leveraging state-of-the-art processes. Learn more about our services.

Target products collection

Go to LATS2/KPM products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdf MSDS
pdf Datasheet

Product information

Catalog No. Product Name lentivirus Grade lentivirus quantity
vGMLP-SPh-020 Human LATS2 Lentivirus particle Pilot Grade 1.0E+8TU
5.0E+8TU
1.0E+9TU
Research Grade 1.0E+8TU
5.0E+8TU
1.0E+9TU
GMP-like Grade inquiry
GMP Grade inquiry


Product Description

Catalog ID vGMLP-SPh-020
Gene Name LATS2
Accession Number NM_014572
Gene ID 26524
Species Human
Product Type Lentivirus particle (overexpression)
Insert Length 3267 bp
Gene Alias KPM
Fluorescent Reporter ZsGreen
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGAGGCCAAAGACTTTTCCTGCCACGACTTATTCTGGAAATAGCCGGCAGCGACTGCAAGAGATTCGTGAGGGGTTAAAACAGCCATCCAAGTCTTCGGTTCAGGGGCTACCCGCAGGACCAAACAGTGACACTTCCCTGGATGCCAAAGTCCTGGGGAGCAAAGATGCCACCAGGCAGCAGCAGCAGATGAGAGCCACCCCAAAGTTCGGACCTTATCAGAAAGCCTTGAGGGAAATCAGATATTCCTTGTTGCCTTTTGCTAATGAATCGGGCACCTCTGCAGCTGCAGAAGTGAACCGGCAAATGCTGCAGGAACTGGTGAACGCAGGATGCGACCAGGAGATGGCTGGCCGAGCTCTCAAGCAGACTGGCAGCAGGAGCATCGAGGCCGCCCTGGAGTACATCAGCAAGATGGGCTACCTGGACCCGAGGAATGAGCAGATTGTGCGGGTCATTAAGCAGACCTCCCCAGGAAAGGGGCTCATGCCAACCCCAGTGACGCGGAGGCCCAGCTTCGAAGGAACCGGCGATTCGTTTGCGTCCTACCACCAGCTGAGCGGTACCCCCTACGAGGGCCCAAGCTTCGGCGCTGACGGCCCCACGGCGCTGGAGGAGATGCCGCGGCCGTACGTGGACTACCTTTTCCCCGGAGTCGGCCCCCACGGGCCCGGCCACCAGCACCAGCACCCACCCAAGGGCTACGGTGCCAGCGTAGAGGCAGCAGGGGCACACTTCCCGCTGCAGGGCGCGCACTACGGGCGGCCGCACCTGCTGGTGCCTGGGGAACCCCTGGGCTACGGAGTGCAGCGCAGCCCCTCCTTCCAGAGCAAGACGCCGCCGGAGACCGGGGGTTACGCCAGCCTGCCCACGAAGGGCCAGGGAGGACCGCCAGGCGCCGGCCTCGCTTTCCCACCCCCTGCCGCCGGGCTCTACGTGCCGCACCCACACCACAAGCAGGCCGGTCCCGCGGCCCACCAGCTGCATGTGCTGGGCTCCCGCAGCCAGGTGTTCGCCAGCGACAGCCCCCCGCAGAGCCTGCTCACTCCCTCGCGGAACAGCCTCAACGTGGACCTGTATGAATTGGGCAGCACCTCCGTCCAGCAGTGGCCGGCTGCCACCCTGGCCCGCCGGGACTCCCTGCAGAAGCCGGGCCTGGAGGCGCCGCCGCGCGCGCACGTGGCCTTCCGGCCTGACTGCCCAGTGCCCAGCAGGACCAACTCCTTCAACAGCCACCAGCCGCGGCCCGGTCCGCCTGGCAAGGCCGAGCCCTCCCTGCCCGCCCCCAACACCGTGACGGCTGTCACGGCCGCGCACATCTTGCACCCGGTGAAGAGCGTGCGTGTGCTGAGGCCGGAGCCGCAGACGGCTGTGGGGCCCTCGCACCCCGCCTGGGTGCCCGCGCCTGCCCCGGCCCCCGCCCCCGCCCCCGCCCCGGCTGCGGAGGGCTTGGACGCCAAGGAGGAGCATGCCCTGGCGCTGGGCGGCGCAGGCGCCTTCCCGCTGGACGTGGAGTACGGAGGCCCAGACCGGAGGTGCCCGCCTCCGCCCTACCCGAAGCACCTGCTGCTGCGCAGCAAGTCGGAGCAGTACGACCTGGACAGCCTGTGCGCAGGCATGGAGCAGAGCCTCCGTGCGGGCCCCAACGAGCCCGAGGGCGGCGACAAGAGCCGCAAAAGCGCCAAGGGGGACAAAGGCGGAAAGGATAAAAAGCAGATTCAGACCTCTCCCGTTCCCGTCCGCAAAAACAGCAGAGACGAAGAGAAGAGAGAGTCACGCATCAAGAGCTACTCGCCATACGCCTTTAAGTTCTTCATGGAGCAGCACGTGGAGAATGTCATCAAAACCTACCAGCAGAAGGTTAACCGGAGGCTGCAGCTGGAGCAAGAAATGGCCAAAGCTGGACTCTGTGAAGCTGAGCAGGAGCAGATGCGGAAGATCCTCTACCAGAAAGAGTCTAATTACAACAGGTTAAAGAGGGCCAAGATGGACAAGTCTATGTTTGTCAAGATCAAAACCCTGGGGATCGGTGCCTTTGGAGAAGTGTGCCTTGCTTGTAAGGTGGACACTCACGCCCTGTACGCCATGAAGACCCTAAGGAAAAAGGATGTCCTGAACCGGAATCAGGTGGCCCACGTCAAGGCCGAGAGGGACATCCTGGCCGAGGCAGACAATGAGTGGGTGGTCAAACTCTACTACTCCTTCCAAGACAAAGACAGCCTGTACTTTGTGATGGACTACATCCCTGGTGGGGACATGATGAGCCTGCTGATCCGGATGGAGGTCTTCCCTGAGCACCTGGCCCGGTTCTACATCGCAGAGCTGACTTTGGCCATTGAGAGTGTCCACAAGATGGGCTTCATCCACCGAGACATCAAGCCTGATAACATTTTGATAGATCTGGATGGTCACATTAAACTCACAGATTTCGGCCTCTGCACTGGGTTCAGGTGGACTCACAATTCCAAATATTACCAGAAAGGGAGCCATGTCAGACAGGACAGCATGGAGCCCAGCGACCTCTGGGATGATGTGTCTAACTGTCGGTGTGGGGACAGGCTGAAGACCCTAGAGCAGAGGGCGCGGAAGCAGCACCAGAGGTGCCTGGCACATTCACTGGTGGGGACTCCAAACTACATCGCACCCGAGGTGCTCCTCCGCAAAGGGTACACTCAACTCTGTGACTGGTGGAGTGTTGGAGTGATTCTCTTCGAGATGCTGGTGGGGCAGCCGCCCTTTTTGGCACCTACTCCCACAGAAACCCAGCTGAAGGTGATCAACTGGGAGAACACGCTCCACATTCCAGCCCAGGTGAAGCTGAGCCCTGAGGCCAGGGACCTCATCACCAAGCTGTGCTGCTCCGCAGACCACCGCCTGGGGCGGAATGGGGCCGATGACCTGAAGGCCCACCCCTTCTTCAGCGCCATTGACTTCTCCAGTGACATCCGGAAGCAGCCAGCCCCCTACGTTCCCACCATCAGCCACCCCATGGACACCTCGAATTTCGACCCCGTAGATGAAGAAAGCCCTTGGAACGATGCCAGCGAAGGTAGCACCAAGGCCTGGGACACACTCACCTCGCCCAATAACAAGCATCCTGAGCACGCATTTTACGAATTCACCTTCCGAAGGTTCTTTGATGACAATGGCTACCCCTTTCGATGCCCAAAGCCTTCAGGAGCAGAAGCTTCACAGGCTGAGAGCTCAGATTTAGAAAGCTCTGATCTGGTGGATCAGACTGAAGGCTGCCAGCCTGTGTACGTGTAG
ORF Protein Sequence MRPKTFPATTYSGNSRQRLQEIREGLKQPSKSSVQGLPAGPNSDTSLDAKVLGSKDATRQQQQMRATPKFGPYQKALREIRYSLLPFANESGTSAAAEVNRQMLQELVNAGCDQEMAGRALKQTGSRSIEAALEYISKMGYLDPRNEQIVRVIKQTSPGKGLMPTPVTRRPSFEGTGDSFASYHQLSGTPYEGPSFGADGPTALEEMPRPYVDYLFPGVGPHGPGHQHQHPPKGYGASVEAAGAHFPLQGAHYGRPHLLVPGEPLGYGVQRSPSFQSKTPPETGGYASLPTKGQGGPPGAGLAFPPPAAGLYVPHPHHKQAGPAAHQLHVLGSRSQVFASDSPPQSLLTPSRNSLNVDLYELGSTSVQQWPAATLARRDSLQKPGLEAPPRAHVAFRPDCPVPSRTNSFNSHQPRPGPPGKAEPSLPAPNTVTAVTAAHILHPVKSVRVLRPEPQTAVGPSHPAWVPAPAPAPAPAPAPAAEGLDAKEEHALALGGAGAFPLDVEYGGPDRRCPPPPYPKHLLLRSKSEQYDLDSLCAGMEQSLRAGPNEPEGGDKSRKSAKGDKGGKDKKQIQTSPVPVRKNSRDEEKRESRIKSYSPYAFKFFMEQHVENVIKTYQQKVNRRLQLEQEMAKAGLCEAEQEQMRKILYQKESNYNRLKRAKMDKSMFVKIKTLGIGAFGEVCLACKVDTHALYAMKTLRKKDVLNRNQVAHVKAERDILAEADNEWVVKLYYSFQDKDSLYFVMDYIPGGDMMSLLIRMEVFPEHLARFYIAELTLAIESVHKMGFIHRDIKPDNILIDLDGHIKLTDFGLCTGFRWTHNSKYYQKGSHVRQDSMEPSDLWDDVSNCRCGDRLKTLEQRARKQHQRCLAHSLVGTPNYIAPEVLLRKGYTQLCDWWSVGVILFEMLVGQPPFLAPTPTETQLKVINWENTLHIPAQVKLSPEARDLITKLCCSADHRLGRNGADDLKAHPFFSAIDFSSDIRKQPAPYVPTISHPMDTSNFDPVDEESPWNDASEGSTKAWDTLTSPNNKHPEHAFYEFTFRRFFDDNGYPFRCPKPSGAEASQAESSDLESSDLVDQTEGCQPVYV

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-T18390-Ab Anti-LATS2 monoclonal antibody
    Target Antigen GM-Tg-g-T18390-Ag LATS2 protein
    ORF Viral Vector pGMAD000587 Human LATS2 Adenovirus plasmid
    ORF Viral Vector pGMLP-SPh-020 Human LATS2 Lentivirus plasmid
    ORF Viral Vector pGMAP-SPh-160 Human LATS2 Adenovirus plasmid
    ORF Viral Vector vGMAD000587 Human LATS2 Adenovirus particle
    ORF Viral Vector vGMLP-SPh-020 Human LATS2 Lentivirus particle
    ORF Viral Vector vGMAP-SPh-160 Human LATS2 Adenovirus particle


    Target information

    Target ID GM-T18390
    Target Name LATS2
    Gene ID 26524, 50523, 699957, 305922, 101093824, 477343, 508208, 100050150
    Gene Symbol and Synonyms 4932411G09Rik,KPM,LATS2
    Uniprot Accession Q9NRM7
    Uniprot Entry Name LATS2_HUMAN
    Protein Sub-location Introcelluar Protein
    Category Therapeutics Target
    Disease Cancer
    Gene Ensembl ENSG00000150457
    Target Classification Kinase, Tumor-associated antigen (TAA)

    This gene encodes a serine/threonine protein kinase belonging to the LATS tumor suppressor family. The protein localizes to centrosomes during interphase, and early and late metaphase. It interacts with the centrosomal proteins aurora-A and ajuba and is required for accumulation of gamma-tubulin and spindle formation at the onset of mitosis. It also interacts with a negative regulator of p53 and may function in a positive feedback loop with p53 that responds to cytoskeleton damage. Additionally, it can function as a co-repressor of androgen-responsive gene expression. [provided by RefSeq, Jul 2008]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.